Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EGFR Tyrosine Kinase Inhibitor Combined With Concurrent or Sequential Chemotherapy for Advanced Lung Cancer Patients of Gradual Progression After First-line EGFR-TKI Therapy: a Randomized Controlled Study

NCT03544814 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT03544814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03544814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EGFR Tyrosine Kinase Inhibitor Combined With Concurrent or Sequential Chemotherapy for Advanced Lung Cancer Patients of Gradual Progression After First-line EGFR-TKI Therapy: a Randomized Controlled Study
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2015
Completion date
December 30, 2017
Enrollment
99 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, lung adenocarcinoma